



Monday, January 10, 2011

Resolvix sells dry eye drug to partner Celtic Therapeutics

By Rodney H. Brown

Related News

[Rib-X raises \\$20M to develop antibiotics](#) [January 11, 2011]

[Epizyme enters lucrative GSK alliance](#) [January 10, 2011]

[New pharmaceuticals startup Dekkun raises \\$10M](#) [January 10, 2011]

[Civitas spins out Alkermes' inhaled drug tech with \\$20M financing](#) [January 10, 2011]

[Amarin expecting \\$100M financing](#) [January 7, 2011]

Cambridge-based Resolvix Pharmaceuticals Inc. is selling and licensing the rights to a drug to treat dry eye syndrome and other ophthalmic conditions to Celtic Therapeutics Holdings LP that the two companies had been working on under a previous agreement. No terms of the deal were released.

Based in New York, Celtic Therapeutics Holdings is described as the successor firm to Celtic Pharma, the U.S. Virgin Islands company with which Resolvix entered a [development deal](#) back in October. At the time, Celtic had been given the option to acquire the rights to the RX-10045, the late-stage treatment for dry eye syndrome developed by Resolvix, an option it is now exercising.

While financial terms of the deal were not disclosed, officials of the two companies did state in a release that it will include upfront payment, near-term milestone payments and funding for 100 percent of future development costs. The deal also gives Celtic Therapeutics the option to license rights to and develop a second Resolvix compound in a topical formulation for ophthalmic indications.

The basis of RX-10045 are resolvins, a recently discovered family of naturally-occurring, small molecules that Resolvix officials said can be targeted to treat a wide range of diseases, including asthma,

atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvix will keep working on developing drugs based on resolvins for non-ophthalmic indications.

RX-10045 is a topical eye drop that has completed a large Phase 2 trial in chronic dry eye. Resolvix officials said RX-10045 is set up to begin a Phase 3 study this year.

[Like](#) Be the first of your friends to like this.

Add your comment, and share it via Facebook, LinkedIn, Yahoo and more. Edit your Disqus profile settings.

Input fields for social sharing (Facebook, LinkedIn, Yahoo, etc.)

Required: Please login below to comment.

Text area for user comment: "Type your comment here."

Post as ...

Showing 0 comments

Sort by [Popular now](#) [Subscribe by email](#) [Subscribe by RSS](#)

How confident are you that your company will reduce its carbon emissions by 25 percent of 1990 levels in the next 10 years?

Very confident – We've got the whole shabang – web conferencing, energy-efficient lighting and renewable energy

18%

Somewhat confident – We recycle and we've eliminated paper cups in the kitchen so far

23%

Not confident – We're still leaving the lights on after hours

38%

Don't know – I do my part, but not sure about the company

21%

[View All Surveys](#)

Stay Informed

Check which newsletter you'd like to receive.

- TechFlash (Daily)
- FinanceFlash (Daily)
- BioFlash (Daily)
- GreenFlash (Weekly)
- Startup Report (Weekly)
- Breaking news, MHT events, local announcements
- RSS feeds



Enter the words above:

Input field for CAPTCHA verification

Get another CAPTCHA
Get an audio CAPTCHA
Help

Your email:


Input field for email address

[Submit](#)

Find us on Facebook



1,124 people like Mass High Tech



Facebook social plugin

Reactions

SHAPE_Society 19 hours ago

From [Twitter](#) via [BackType](#)

Resolvix sells dry eye drug to partner Celtic Therapeutics - Mass High Tech: The basis of RX-10045 are resolvins... <http://bit.ly/fLqjKs>


Trackback URL

////////////////////////////////////

[New England Tech Directory](#) | [Subscribe](#) | [Advertise](#) | [Community/Events](#) | [About Us](#) | [Search](#) | [RSS Feeds](#) | [Technorati](#)

© 2008 American City Business Journals, Inc. and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of bizjournals.

Affiliate publications: [ACBJ.com](#), [Boston Business Journal](#), [Bizjournals.com](#), [Portfolio.com](#), [Wired.com](#)

Web Site Developed by  **neptune web**

Use of, registration on, this site constitutes acceptance of our [User Agreement](#). Please read our [Privacy Policy](#) (updated) A publishing partner with [Portfolio](#)
